EirGenix Inc.
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatme… Read more
Market Cap & Net Worth: EirGenix Inc. (6589)
EirGenix Inc. (TW:6589) has a market capitalization of $524.97 Million (NT$17.37 Billion) as of March 18, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #12324 globally and #370 in its home market, demonstrating a -4.01% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying EirGenix Inc.'s stock price NT$57.40 by its total outstanding shares 302600211 (302.60 Million).
EirGenix Inc. Market Cap History: 2025 to 2026
EirGenix Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $564.30 Million to $524.97 Million (0.00% CAGR).
EirGenix Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how EirGenix Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6589 by Market Capitalization
Companies near EirGenix Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to EirGenix Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
EirGenix Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, EirGenix Inc.'s market cap moved from $564.30 Million to $ 524.97 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$524.97 Million | -6.97% |
| 2025 | NT$564.30 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of EirGenix Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $524.97 Million USD |
| MoneyControl | $524.97 Million USD |
| MarketWatch | $524.97 Million USD |
| marketcap.company | $524.97 Million USD |
| Reuters | $524.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.